ArticleHaematologica2010
Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.
Article in Haematologica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis.Blood advances · 2023Pooled it
- Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.Annals of hematology · 2022Article
- Distinctive and common features of moderate aplastic anaemia.British journal of haematology · 2020Article
- Diagnosis and Treatment of Aplastic Anemia.Current treatment options in oncology · 2017Review
- Monoclonal gammopathy-associated pure red cell aplasia.British journal of haematology · 2016Article
- Article
- Front-line immunosuppressive treatment of acquired aplastic anemia.Bone marrow transplantation · 2013Review
- The progression risk factors of children with transfusion-independent non-severe aplastic anemia.International journal of hematology · 2013Article
- Aplastic anemia: immunosuppressive therapy in 2010.Pediatric reports · 2011Article
- Pure Red Cell Aplasia Following Interleukin-2 Therapy.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPure red cell aplasia and moderate aplastic anemia are marrow failure states with an immune pathogenesis. Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and pure red cell aplasia (PRCA) patients with daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor; we now report our long-term experience with a larger cohort of patients. DESIGN AND
methodsAfter a median follow-up period of 4.8 years, 19 of 45 (42%) evaluable mAA patients and 10 of 26 (38%) patients with PRCA responded by three months and 2 additional mAA patients responded by six months following administration of the drug.
resultsSeven of 28 (25%) mAA patients achieved long-term packed red blood cell PRBC transfusion independence, and all PRCA responders achieved long-term transfusion PRBC transfusion independence.
conclusionsRed cell transfusion-independence prior to treatment in mAA patients predicted response. The only significant adverse treatment-related events were transient rashes and arthralgias. Daclizumab is safe and effective, and produces lengthy remissions in patients with PRCA and mAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.